As a complete complement solutions provider, Creative Biolabs has the expertise to optimize each stage of complement to ensure you get the results you want. We will work with you as part of your team to not only provide you with comprehensive quality data, but also timely and effective solutions to any challenges you face.
C1q Biochemical Analysis Protocol
C1q is of interest to many laboratories investigating structural-functional relationships since it is a remarkable multifunctional molecule, which possesses the ability to recognize and bind an amazing variety of structurally different self- and non-self-target molecules and thus participates in immunological processes with great importance. Such studies ultimately require biochemically pure and functionally active C1q. Western blot analysis is used for the identification of purified C1q chains, fragments, and recombinant derivatives.
Fig.1 Flow chart of C1q biochemical analysis protocol. (Creative Biolabs)
Published Data
Fig.2 Analysis of C1q binding in the samples.1
One of the functional roles of IgG antibodies is complement-dependent cytotoxicity (CDC). This involves initiating the complement cascade through the binding of their Fc region’s CH2 domain to C1q. A schematic of C1q interaction with IgG is depicted above. Various studies in the literature have performed C1q binding analyses using methodologies such as SPR or ELISA; here, ELISA was employed. In this study, the binding efficiencies of AVT, ALT, ZIR, and MVA were assessed via direct ELISA under consistent conditions.
Complement-related Services and Products
-
Complement Products
-
Complement Test Services
Creative Biolabs provides leading services and products in the field of complement research, and our customers include scientists from the medical and academic communities. If you do not find the complement services and products you are interested in on our website, you can contact our experts directly for more information.
Reference
-
Gürel, Büşra, et al. "Optimized methods for analytical and functional comparison of biosimilar mAb drugs: A case study for Avastin, Mvasi, and Zirabev." Scientia Pharmaceutica 90.2 (2022): 36. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.
Related Sections:
